263 Great Valley Parkway
Suite 160
Malvern, PA 19355
United States
484 328 4701
https://www.ocugen.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 56
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Shankar Musunuri M.B.A., MBA, Ph.D. | Co-Founder, Chairman & CEO | 845.2k | 6.67M | 1964 |
Dr. Uday B. Kompella Ph.D. | Co-founder & Independent Director | 44k | N/A | 1967 |
Ms. Jessica Crespo CPA, CPA | Chief Accounting Officer, Sr. VP of Fin. and VP of Corp. Controller & Treasurer | N/A | N/A | 1977 |
Dr. Arun Upadhyay Ph.D. | Chief Scientific Officer | N/A | N/A | N/A |
Ms. Tiffany Hamilton M.B.A. | Head of Corp. Communications | N/A | N/A | N/A |
Ms. Zara Gaudioso | AVP, Head of HR & Chief of Staff | N/A | N/A | N/A |
Mr. Michael Shine | Sr. VP of Commercial | N/A | N/A | N/A |
Dr. Robert J. Hopkins FACP, M.D., M.P.H. | Chief Medical Officer | N/A | N/A | N/A |
Mr. Quan Anh Vu | Chief Bus. Officer | N/A | N/A | 1973 |
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Ocugen, Inc.’s ISS governance QualityScore as of 1 February 2023 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 8; Compensation: 7.